Ionis Pharmaceuticals (IONS) Current Deferred Revenue (2009 - 2026)
Ionis Pharmaceuticals (IONS) posted quarterly Current Deferred Revenue of $73.8 million for Q2 2026, down 2.73% year-over-year from $75.9 million in Q2 2025, and up 6.7% quarter-over-quarter from $69.2 million in Q1 2026.
Ionis Pharmaceuticals (IONS) Current Deferred Revenue (2009 - 2026) Analysis & Trends
Ionis Pharmaceuticals' Current Deferred Revenue history runs 18 years deep, the most recent figure standing at $73.8 million for Q2 2026.
- In Q2 2026, Current Deferred Revenue fell 2.73% year-over-year to $73.8 million; the TTM figure through Jun 2026 stood at $73.8 million (down 2.73% YoY), while the FY2025 annual figure was $73.8 million, down 6.62% from the prior year.
- Current Deferred Revenue for Q2 2026 stood at $73.8 million, up from $69.2 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $204.8 million in Q3 2023, with the low at $4.3 million in Q1 2025.
- The 5-year median for Current Deferred Revenue is $91.0 million (2022), against an average of $92.9 million.
- The sharpest annual moves came in 2025 and 2026: Current Deferred Revenue sank 96.7% in 2025, then jumped 1509.28% in 2026.
- Ionis Pharmaceuticals' Current Deferred Revenue stood at $90.6 million in 2022, then surged by 66.85% to $151.1 million in 2023, then tumbled by 47.73% to $79.0 million in 2024, then slipped by 6.62% to $73.8 million in 2025, then grew by 0.1% to $73.8 million in 2026.
- Business Quant data shows IONS's Current Deferred Revenue at $73.8 million in Q2 2026, $69.2 million in Q1 2026, and $73.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ionis Pharmaceuticals | 9.48 Bn | 7.43 Bn | 265.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 73.84 Mn |
| Mar 31, 2026 | 69.20 Mn |
| Dec 31, 2025 | 73.76 Mn |
| Sep 30, 2025 | 76.99 Mn |
| Jun 30, 2025 | 75.91 Mn |
| Mar 31, 2025 | 4.30 Mn |
| Dec 31, 2024 | 78.99 Mn |
| Sep 30, 2024 | 76.02 Mn |
| Jun 30, 2024 | 94.07 Mn |
| Mar 31, 2024 | 130.41 Mn |
| Dec 31, 2023 | 151.13 Mn |
| Sep 30, 2023 | 204.82 Mn |
| Jun 30, 2023 | 96.25 Mn |
| Mar 31, 2023 | 92.34 Mn |
| Dec 31, 2022 | 90.58 Mn |
| Sep 30, 2022 | 99.51 Mn |
| Jun 30, 2022 | 93.39 Mn |
| Mar 31, 2022 | 91.44 Mn |
| Dec 31, 2021 | 97.71 Mn |
| Sep 30, 2021 | 97.93 Mn |